Lab21 Limited, the Cambridge, UK-based specialist in personalised medicine and clinical diagnostics, has announced that it has acquired Microgen Bioproducts Ltd a UK company specialising in the development, manufacture and sale of diagnostic tests to identify diseases and organisms which pose a threat to health.
Microgen Bioproducts’ expertise in microbiological assay development and commercialisation complements Lab21’s extensive diagnostics portfolio particularly in the infectious disease market. This transaction provides further expansion of Lab21’s distribution channel in key territories including the US, UK, Europe and Asia.
Graham Mullis, CEO of Lab21 said: “Microgen Bioproducts is a well established and profitable business which will significantly contribute to our growth plans in our core products division. This acquisition highlights Lab21’s commitment to continuing its exciting roll-up strategy and we expect to bring other high quality acquisitions into the Group during 2011.”
Dan Deery, Managing Director of Microgen Bioproducts added: “Lab21 has built a strong reputation, with a global reach and innovative products. We are delighted to join forces with them.”
The acquisition follows a strong year for the products division which saw the company’s first product registration in China; its first US product approval and in addition to the launch of a number of new products, further expansion of its distribution network.